In this study, we used Sanger sequencing (targeted sequencing) to demonstrate that our developed ABL-targeted therapy had no off-target effects on similar gene sequences in the pool of gene-edited cells, indicating that the ABL-based CRISPR/Cas9 gene editing system is highly specific and would be safe for CML therapy. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.